Noeli S. M. Silva

Noeli S. M. Silva

Auto-generated profile, based on publicly available information

Noeli S. M. Silva

Biochemistry and Biophysics of Proteins Group, Department of Chemistry and Molecular Physics, São Carlos Institute of Chemistry, University of São Paulo, 400 Trabalhador São-carlense Avenue, 13560-970 São Carlos, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
NSNoeli S.M. Silva
Noeli S.M. Silva
DBDayane E. Bertolino-Reis
Dayane E. Bertolino-Reis
PDPaulo R. Dores-Silva
Paulo R. Dores-Silva
FAFátima B. Anneta
Fátima B. Anneta
TSThiago V. Seraphim
Thiago V. Seraphim
JBJulio Cesar Borges
Julio Cesar Borges

1 March 2018 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
NSNoeli S.M. Silva
Noeli S.M. Silva
TSThiago V. Seraphim
Thiago V. Seraphim
KMKarine Minari
Karine Minari
LBLeandro R.S. Barbosa
Leandro R.S. Barbosa
JBJulio Cesar Borges
Julio Cesar Borges

19 January 2026 in ACS Omega
Verified
Journal Article
Open access
ESErica C. Silva
Erica C. Silva
NSNoeli S. M. Silva
Noeli S. M. Silva
FSFelipe S. Soto
Felipe S. Soto
JBJulio Cesar Borges
Julio Cesar Borges
Valtencir ZucolottoValtencir Zucolotto
Valtencir Zucolotto
Early detection of any form of cancer increases the number of successful treatments, but a lack of predictive biomarkers is limiting progress as low tumor-to-background ratios cause current tumor biomarkers to miss early signs of disease. Activity-based nanosensors, sensing nanoparticles administered in a prodiagnostic form, tackle this limitation by generating synthetic biomarkers at disease sites and leveraging enzymatic turnover and urinary enrichment to amplify tumor signals that would otherwise remain hidden. We inform that successful activity-based nanosensor tumor accumulation requires more than engineered nanoparticles with size, surface charge, and shape to ease the entry into tumors and the use of tumor models known to have vasculature permeable to nanoparticles. We found that a protease activity-based nanosensor with a half-life amenable to distribution in organs did not accumulate in an invasive mammary tumor model characterized by diffusive and active transport entry of nanoparticles with sizes within our nanosensor size distribution. Moreover, nonspecific and off-target activations decreased the nanosensor half-life in blood, which further aided in lowering the entry into tumors, yielding no distinct increases in the tumor activity signal in urine. These findings prompted refinements of the current design criteria of activity-based nanosensors, pushing for the development of nanosensors that rely on more specific properties of tumor proteolytic activity.